{"public_id":"cl_29d81a541e2b3fd943943d662bc7fdd3","status":"active","superseded_by_public_id":null,"corpus_id":8302472,"text":"Adherence is strongly associated with major molecular response and complete molecular response in chronic-phase chronic myeloid leukemia patients treated with imatinib after complete cytogenetic response.","confidence":0.98,"paper":{"corpus_id":8302472,"title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","url":"https://sah.borca.ai/papers/8302472"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_17cd7cde450541fe99676bfe3a32e529","name":"adherence","description":"The extent to which patients took imatinib as prescribed, measured with a microelectronic monitoring device.","types":["measure"],"url":"https://sah.borca.ai/concepts/co_17cd7cde450541fe99676bfe3a32e529"},{"public_id":"co_e7451c30c24eecfb9b2da04cc58f130b","name":"complete molecular response","description":"A molecular response characterized by undetectable BCR-ABL1 transcripts in the assay used.","types":["clinical response"],"url":"https://sah.borca.ai/concepts/co_e7451c30c24eecfb9b2da04cc58f130b"},{"public_id":"co_eacaee09a4e3b378dd2ebd611e5e5f7c","name":"imatinib","description":"A tyrosine kinase inhibitor used as the treatment in the reported chronic myeloid leukemia cohort.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_eacaee09a4e3b378dd2ebd611e5e5f7c"},{"public_id":"co_f4fe8292dabb51184c7a4dd8a3aa8753","name":"major molecular response","description":"A molecular response defined here as a 3-log reduction in BCR-ABL1 transcripts.","types":["clinical response"],"url":"https://sah.borca.ai/concepts/co_f4fe8292dabb51184c7a4dd8a3aa8753"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_29d81a541e2b3fd943943d662bc7fdd3"}